Avidicure Raises $50M in Seed Financing
Summary
Avidicure, an Amsterdam, The Netherlands-based biotechnology company pioneering an entirely new multifunctional antibody modality with broad applicability in oncology, raised $50m in seed financing. Led by Arthur Lahr, Chief Executive Officer, Avidicure is developing dual agonistic, multifunctional and avidity engineered antibodies, “AVC-Boosters”, that can safely deliver targeted and potent cancer monotherapy. The AVC-Booster design surpasses the best qualities of first-generation antibodies, checkpoint inhibitors, T-cell engagers, and antibody-drug conjugates (ADCs). Avidicure’s fully owned proprietary platform leverages decades of antibody engineering and in silico protein design capabilities, and immunology expertise. The founding management team consists of Arthur Lahr (CEO), Dirk De Naeyer (COO), Robert Friesen (CSO), and Govert Schouten (CBO), The Supervisory Board includes industry veterans Frank Verwiel (Intellia, Aptalis, Bavarian Nordic, Merck & Co.), Martijn Kleijwegt (EQT-LS), Hunter Smith (Rhythm), and Helen Collins (Five Prime, Enliven, Gilead, Amgen).